Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy

Ching-Sheng Hsu, Shih-Jer Hsu, Wei-Liang Liu, Ding-Shinn Chen, Jia-Horng Kao, Ching-Sheng Hsu, Shih-Jer Hsu, Wei-Liang Liu, Ding-Shinn Chen, Jia-Horng Kao

Abstract

The scavenger receptor type B class I(SR-BI) is a receptor for high-density lipoproteins(HDL) and one of entry factors for hepatitis C virus(HCV). We examined the association of single nucleotide polymorphisms(SNPs) of the SCARB1 gene, which encodes SR-BI, with virologic responses to pegylated interferon-based treatment in Asian chronic hepatitis C(CHC) patients. Human genomic and clinical data were collected from 156 consecutive Taiwanese HCV genotype 1 or 2 patients who received pegylated interferon plus ribavirin therapy and 153 non-HCV healthy subjects. Three SNPs(rs10846744, rs5888, and rs3782287) of the SCARB1 gene that have been linked to humans diseases were investigated. rs10846744 rather than rs5888 or rs3782287 was associated with serum HCV RNA level and sustained virologic response(SVR) to pegylated interferon plus ribavirin therapy in CHC patients(GG vs. non-GG genotype, Adjusted Odds Ratio, 95% CI: 0.32, 0.11-0.95, P = 0.039). Among patients with IL28B rs8099917 non-TT genotypes, those with rs10846744 non-GG genotype had a higher SVR rate than those with GG genotypes. In addition, patients with GG genotype had a higher fasting blood glucose level than those with CC genotype. In conclusion, SCARB1 gene polymorphisms may serve as a potential predictor of treatment responses in CHC patients receiving interferon-based therapy. (ClinicalTrials.gov number, NCT02714712).

Conflict of interest statement

Ding-Shinn Chen has consulted for Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Roche, and Merck Sharp & Dohme. Jia-Horng Kao has consulted for Bristol-Myers Squibb, Gilead Sciences, and Novartis; on speaker’s bureau for Roche, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme, and Novartis. All other authors declare no competing financial interests.

References

    1. Williams R. Global challenges in liver disease. Hepatology 44, 521–526 (2006).
    1. Kao J. H. Hepatitis C virus infection in Taiwan: Past, present, and future. J Formos Med Assoc 115, 65–66 (2016).
    1. Panel A. I. H. G. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62, 932–954 (2015).
    1. Hsu C. S. & Kao J. H. Management of hepatitis C patients with decompensated liver disease. Expert Rev Gastroenterol Hepatol (2016).
    1. Strader D. B., Wright T., Thomas D. L. & Seeff L. B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39, 1147–1171 (2004).
    1. Fried M. W. Side effects of therapy of hepatitis C and their management. Hepatology 36, S237–244 (2002).
    1. Lindenbach B. D. & Rice C. M. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 11, 688–700 (2013).
    1. Lindenbach B. D. Virion assembly and release. Curr Top Microbiol Immunol 369, 199–218 (2013).
    1. Acton S. et al.. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518–520 (1996).
    1. Scarselli E. et al.. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21, 5017–5025 (2002).
    1. Edmondson A. C. et al.. Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. Circ Cardiovasc Genet 4, 145–155 (2011).
    1. Teslovich T. M. et al.. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).
    1. Roberts C. G. et al.. Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women. Hum Hered 64, 107–113 (2007).
    1. Acton S. et al.. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler Thromb Vasc Biol 19, 1734–1743 (1999).
    1. Naj A. C. et al.. Association of scavenger receptor class B type I polymorphisms with subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Genet 3, 47–52 (2010).
    1. Manichaikul A. et al.. Association of SCARB1 variants with subclinical atherosclerosis and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 32, 1991–1999 (2012).
    1. Rein-Fischboeck L. et al.. Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease. Biochem Biophys Res Commun 467, 377–382 (2015).
    1. Valacchi G. et al.. Exploring the link between scavenger receptor B1 expression and chronic obstructive pulmonary disease pathogenesis. Ann N Y Acad Sci 1340, 47–54 (2015).
    1. Niemsiri V. et al.. Impact of genetic variants in human scavenger receptor class B type I (SCARB1) on plasma lipid traits. Circ Cardiovasc Genet 7, 838–847 (2014).
    1. Hsu C. S. et al.. Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. Hepatol Int 7, 171–179 (2013).
    1. Hsu C. S. et al.. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 14, 45–54 (2009).
    1. Feng H. et al.. Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice. Arterioscler Thromb Vasc Biol 31, 2543–2551 (2011).
    1. Poordad F. F. & Flamm S. L. Virological relapse in chronic hepatitis C. Antivir Ther 14, 303–313 (2009).
    1. West M. et al.. Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia. J Clin Endocrinol Metab 94, 1451–1457 (2009).
    1. Mineo C. & Shaul P. W. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med 17, 156–161 (2007).
    1. Suchindran S. et al.. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 6, e1000928 (2010).
    1. Gantman A., Fuhrman B., Aviram M. & Hayek T. High glucose stimulates macrophage SR-BI expression and induces a switch in its activity from cholesterol efflux to cholesterol influx. Biochem Biophys Res Commun 391, 523–528 (2010).
    1. Zhang Q. et al.. High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS One 6, e23556 (2011).
    1. Kent A. P. & Stylianou I. M. Scavenger receptor class B member 1 protein: hepatic regulation and its effects on lipids, reverse cholesterol transport, and atherosclerosis. Hepat Med 3, 29–44 (2011).
    1. Ravid Z. et al.. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol 295, G873–885 (2008).
    1. Kasai D. et al.. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol 50, 883–894 (2009).
    1. Hsu C. S. et al.. Metabolic profiles in patients with chronic hepatitis C: a case-control study. Hepatol Int 2, 250–257 (2008).
    1. Harrison S. A. Correlation between insulin resistance and hepatitis C viral load. Hepatology 43, 1168; author reply 1168–1169 (2006).
    1. Hsu C. S. & Kao J. H. Genomic variation-guided management in chronic hepatitis C. Expert Rev Gastroenterol Hepatol 6, 497–506 (2012).
    1. Ghany M. G., Strader D. B., Thomas D. L. & Seeff L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009).
    1. Kim H. C. et al.. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Bmj 328, 983 (2004).
    1. Prati D. et al.. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 44, 679–685 (2006).
    1. Hsu C. S. et al.. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 28, 271–277 (2008).
    1. Yeh S. H. et al.. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 41, 659–666 (2004).
    1. Hsu C. S. et al.. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 50, 310–315 (2007).
    1. Kao J. H. et al.. Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: correlation with genotypes. J Gastroenterol 31, 224–227 (1996).
    1. Ohno O. et al.. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35, 201–207 (1997).
    1. Hsu C. S. et al.. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 108, 3719–3724 (2011).

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe